Education
About Us
Working with TipRanks
Follow Us
ANI Pharmaceuticals Inc (ANIP)
NASDAQ:ANIP
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.41Last Year’s EPS
1.02Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 09, 2025
|% Change Since: -16.13%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
ANI Pharmaceuticals demonstrated strong growth with record revenue and increased guidance, driven by the generics and Cortrophin Gel segments. However, challenges remain with market access and salesforce turnover affecting the retina products. The company is addressing these issues through strategic investments and operational adjustments.Company Guidance
During ANI Pharmaceuticals' Q1 2025 earnings call, the company reported a robust financial performance, achieving record revenue, adjusted EBITDA, and adjusted EPS. Based on the first quarter's success and favorable demand trends, ANI raised its 2025 guidance for total revenues to $768 million to $793 million, reflecting a 25% to 29% growth over 2024. Adjusted non-GAAP EBITDA is now expected to range from $195 million to $205 million, up 25% to 31% from the previous year. The company's revenue for the first quarter was $197.1 million, marking a 43% year-over-year increase. Key drivers included strong performance in the generics segment, which grew by 41% to $98.7 million, and the rare disease segment, particularly Cortrophin Gel, which saw a 43% increase in revenue to $52.9 million. The guidance also maintained expectations for Cortrophin Gel revenues to reach $265 million to $274 million, with ILUVIEN and YUTIQ revenues predicted to be between $97 million and $103 million, despite some market access challenges in the U.S. Additionally, ANI's generics business is projected to experience mid-double-digit growth throughout the year.Record Revenue and Growth
ANI Pharmaceuticals reported record revenue of $197.1 million for Q1 2025, a 43% year-over-year increase on an as-reported basis and 32% on an organic basis. This performance was driven by exceptional growth in generics, Cortrophin Gel, and the brands portfolio.
Increased 2025 Guidance
Based on the strong performance in Q1, ANI Pharmaceuticals raised its 2025 revenue guidance to $768 million to $793 million, representing growth of 25% to 29% over 2024.
Cortrophin Gel Growth
Cortrophin Gel generated $52.9 million in Q1 revenue, up 43% from the first quarter of 2024. The company expects Cortrophin Gel revenues to increase 34% to 38% for the year.
Generics Business Performance
The generics segment delivered strong Q1 revenue of $98.7 million, an increase of 41% over Q1 2024, driven by new product launches and strong base business execution.
Strategic Investments and New Approvals
ANI made strategic moves including the buyout of the royalty obligation on ILUVIEN and YUTIQ, and launched a pre-filled syringe for Cortrophin Gel, which received positive feedback.
---
ANIP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ANIP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 09, 2025 | $71.53 | $66.30 | -7.31% |
Feb 28, 2025 | $54.58 | $61.89 | +13.39% |
Nov 08, 2024 | $58.38 | $61.44 | +5.24% |
Aug 06, 2024 | $59.16 | $63.29 | +6.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ANI Pharmaceuticals Inc (ANIP) report earnings?
ANI Pharmaceuticals Inc (ANIP) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is ANI Pharmaceuticals Inc (ANIP) earnings time?
ANI Pharmaceuticals Inc (ANIP) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ANIP EPS forecast?
ANIP EPS forecast for the fiscal quarter 2025 (Q2) is 1.41.
---